Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

INTRODUCTION. We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer. PATIENTS AND METHODS. Patients received...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Swain, Sandra M., Im, Young-Hyuck, Im, Seock-Ah, Chan, Valorie, Miles, David, Knott, Adam, Clark, Emma, Ross, Graham, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2014
Assuntos:
Breast Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077449/
https://ncbi.nlm.nih.gov/pubmed/24869931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0033
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares